Gnothis is building a next-generation, single-molecule sequencing platform that delivers same-day, personalized genetic answers — right when time-critical clinical decisions are being made.
Contact us Follow on LinkedIn"Same day: sample → insight. One patient, one run, one answer."
Genomics keeps advancing, but insight still arrives too late to change the decisions it was meant to inform. At Gnothis, we are building a next-generation sequencing platform that delivers same-day, personalized genetic answers for time-critical clinical decisions.
The value isn't more data. It's timely data — tighter iteration cycles, no batch bottlenecks, clinicians catching actionable mutations early, and patients who reach the right treatment sooner.
Our ambition: to transform patient care by enabling faster, more informed clinical decisions — accessible to every clinician.
The Greek phrase "gnothi seauton", meaning "know thyself", embodies self-awareness and understanding.
Gnothis' DNA sequencing technology brings this to life by unlocking our genetic code, with accuracy and ease.
We are developing a sequencing instrument that directly analyzes individual DNA molecules — no PCR amplification required. By counting single molecules directly, it removes the delays, amplification bias, and workflow complexity of conventional sequencing, giving physicians actionable genomic information in time to guide treatment.
Gnothis' primary patent covers any method that measures interactions between a single molecule immobilized on a surface and the molecules that bind to it, using light-based detection — a broad scope granting exclusive rights across applications beyond single-molecule DNA sequencing.
Identifies single-molecule binding events with a unique signature.
Ensures exclusivity to bind one molecule to each of several spots.
Ensures every gold spot has exactly one molecule bound to it.
Allows the chips to be reused, reducing cost per run.
The Gnothis team, Stockholm.
Expert in DNA sequencing technologies and single-molecule methods, with experience across multiple scientific disciplines.
Expert in advanced optical instrumentation and microscopy platforms, with industrial experience in clinical genomics.
Expert in assay development and multi-omics methods, with technology commercialization experience.
Expertise spanning finance, entrepreneurship, medicine, photonics, intellectual property, and research & development.
Recognized leader in asset management; experienced board director across five continents.
Senior technology executive in financial services; expert in large-scale global transformations.
Deep cross-industry IP expertise; registered European Patent Attorney and qualified UPC litigator.
Co-founder and CEO of Cobolt; heads the photonics division of a global industrial group.
PhD in Medical Biophysics; co-founder of Gnothis.
Leading pathologist in Cologne; pioneer in cancer genomics and precision oncology.
For investment inquiries, partnerships, or general questions, reach out below.